Kidney damage is a common sequela of several chronic pathologic conditions. Whether biomarkers of kidney damage are prognostic for more severe outcomes is unknown. We measured three urinary biomarkers (kidney injury molecule-1 [KIM-1], IL-18, and albumin) in 3010 individuals enrolled in the Health, Aging and Body Composition (Health ABC) study and used Cox proportional hazards models to investigate the associations of urinary KIM-1/creatinine (cr), IL-18/cr, and albumin/cr (ACR) with all-cause mortality and cardiovascular disease (CVD). Multivariable models adjusted for demographics, traditional CVD risk factors, and eGFR. Mean age of participants was 74 years, 49% of participants were men, and 41% of participants were black. During the median 12.4 years of follow-up, 1450 deaths and 797 CVD outcomes occurred. Compared with the lowest quartile, successive quartiles had the following adjusted hazard ratios (HRs; 95% confidence intervals [95% CIs]) for mortality: KIM-
Over the last decade, several novel urine biomarkers of acute tubular injury have been described. Before any increases in serum creatinine or decline in eGFR, these biomarkers have been shown to identify AKI, 1 mediate kidney injury, and reflect tubular damage and apoptosis. 2, 3 They have also been shown to predict the severity of AKI and in-hospital mortality from multiple causes of AKI, including kidney transplantation, cardiac surgery, and septic shock. [4] [5] [6] [7] [8] [9] [10] [11] Although both urinary kidney injury molecule (KIM-1) and IL-18 were originally identified as markers of AKI, each marker has shown promise as an indicatorof chronic tubular damage and progressive kidney disease. Urinary levels of KIM-1 are elevated in various forms of CKD and associated with the severity of pathology, including fibrosis and inflammation. 12, 13 Other studies have noted higher urinary IL-18 levels in patients with nephrotic syndrome and other forms of CKD compared with controls and the ability to predict severity of kidney disease. 14, 15 Recent work from our group has suggested that urinary KIM-1 and IL-18 may identify ambulatory persons who are at risk for kidney function decline as well as mortality. In the Multi-Ethnic Study of Atherosclerosis (MESA), elevated urinary KIM-1 levels were associated with kidney function decline using a case control design, 16 whereas in the Women's Interagency HIV Study (WIHS), elevated levels of urinary IL-18 and KIM-1 were each associated with both kidney function decline and all-cause mortality. 17, 18 However, to our knowledge, there are no large studies in the general population that have evaluated whether markers of tubular injury are associated with all-cause mortality or cardiovascular disease (CVD). On kidney biopsy, the severity of tubular atrophy and the severity of fibrosis are the most reliable pathologic features for prediction of progression to kidney failure in nearly all etiologies of kidney disease. [19] [20] [21] Biomarkers of tubular injury, therefore, may also be associated with the consequences of CKD, such as CVD and mortality. There are also no studies that have compared associations of these newer tubular kidney injury markers (with the established urinary biomarker albuminuria) with all-cause mortality and CVD. In this analysis, we, therefore, evaluated the relationships of urinary KIM-1, IL-18, and albumin with all-cause and CVD in the Health, Aging and Body Composition (Health ABC) study, which had an elderly population at high risk for mortality and CVD.
RESULTS
In total, 3010 participants had urine available for measurement of KIM-1, IL-18, and albumin to creatinine ratio (ACR). Median (interquartile range) levels of KIM-1, IL-18, and urine ACR (UACR) were 794 (406, 1442) pg/ml, 29 (13, 57) pg/ml, and 8.3 (4.6, 20. 3) mg/g, respectively. Less than 1% of KIM-1, 5.25% of IL-18, 5.8% of albuminuria, and 5.9% of urine creatinine values were set to the lowest detection limit. Mean age of the populationwas 74 years, 49% of participants were men, 41% of participants were black, 24% of participants had diabetes, and 22% of participants had prevalent coronary heart disease (CHD); 17% of participants had eGFR cys ,60 ml/min per 1 (Table 1 ). Participants with higher urinary KIM-1/creatinine (cr) were more likely to be white, have diabetes or CHD, have higher levels of C-reactive protein (CRP) and UACR, and have lower levels of serum albumin and eGFR cys . Participants with higher IL-18/cr were more likely to be women, white, and smokers, have lower prevalence of CHD, and have higher levels of CRP, ACR, and eGFR cys (Supplemental Table 1 ). Participants with higher levels of UACR were more likely to be black, have diabetes, hypertension, and CHD, have higher CRP, and have lower eGFR cys (Supplemental Table 2 ). KIM-1 was significantly correlated with UACR (r=0.17, P,0.01), eGFR cys (r=20.08, P,0.01), and IL-18 (r=0.19, P,0.01). IL-18 was also significantly correlated with eGFR cys (r=0.10, P,0.01) and ACR (r=0.17, P,0.01). 
All-Cause Mortality and Urine Biomarkers
There were 1450 deaths and median follow-up of 12.4 years.
KIM-1/cr
The mortality rate was highest in the highest quartile of KIM-1/cr relative to the other three quartiles ( Figure 1A) . In continuous models, KIM-1/cr was associated with an increased risk of mortality in demographic-and risk factor-adjusted models, but this finding was attenuated after adjustment for eGFR cys and UACR. In the quartile analysis, the top quartile of KIM-1/cr was associated with approximately a 50% higher mortality risk compared with the lowest quartile after adjustment for risk factors and remained independently associated with a 28% higher risk of mortality after adjustment for UACR and eGFR cys ( Table 2) .
IL-18/cr
Quartiles of IL-18/cr had a weak association with mortality ( Figure 1A) . In continuous models, IL-18/cr was modestly associated with mortality in demographic models, but this finding was attenuated by adjustment for kidney-related risk factors. In quartile analyses, the top two quartiles were also modestly associated with higher mortality, but these findings were attenuated and no longer significant after adjustment for risk factors eGFR cys and UACR (Table 2) .
UACR
Higher quartiles of UACR had increased mortality rates compared with the lowest quartile ( Figure 1A) . In continuous models, higher UACR was associated with all-cause mortality in unadjusted and fully adjusted models (Table 2) . In quartile analyses, the top two quartiles were independently associated with a 24% and 63% increased risk of mortality compared with the lowest quartile, respectively.
CVD and Urine Biomarkers
There were 797 CVD outcomes with median follow-up of 11.8 years. Associations of KIM-1/cr and IL-18/cr were weak for the CVD outcome ( Figure 1B) . In adjusted models, we found no association between either KIM-1/cr or IL-18/cr with CVD. In contrast, UACR was a risk factor for CVD in all unadjusted and adjusted models (Table 3) .
Interactions
We found no interaction of KIM-1/cr or IL-18/cr with eGFR, UACR, sex, or race for the outcomes of either mortality or CVD (P.0.05 for all).
Sensitivity Analyses KIM-1/cr on a linear scale (but not in quartiles) showed a relatively small but significant association with progression of kidney disease in fully adjusted analyses using linear mixed models (Supplemental Table 3 ). There was no association, however, of KIM-1/cr with rapid progression (Supplemental Table 4 ). IL-18/cr was not associated with progression using either outcome, whereas ACR was associated with progression of CKD using either method (Supplemental Tables 3 and 4) .
We noted some degree of attenuation in the relationship of KIM-1 with mortality when we adjusted for either baseline kidney function (ACR and eGFR cys ) or time-dependent changes in eGFR cys (Table 2 ). In additional analyses that adjusted for serum bicarbonate, parathyroid hormone, phosphorus, and hemoglobin, there was no significant difference in the results (Supplemental Table 5 ). Similarly, in analyses that adjusted for hemoglobin A1C and time-dependent changes in systolic BP (SBP), there was no significant difference in the results (Supplemental Table 6 ).
DISCUSSION
To our knowledge, this study is one of the largest studies to date and one of the first in the general population that has evaluated 136 (21) 135 (21) 136 (20) 136 (22) the relationship of tubular injury markers with risk for mortality and CVD. Our results showed that urinary KIM-1/cr was moderately associated with mortality in demographic-and risk factor-adjusted models; however, there was attenuation after adjustment for eGFR and ACR, resulting in a modest independent association of urinary KIM-1/cr with mortality. We noted no independent association between urinary KIM-1/cr and CVD or between urinary IL-18/cr and either all-cause mortality or CVD. In contrast to the tubular injury markers, we noted a significant and consistent relationship of UACR with both mortality and CVD. Few studies have evaluated the association between urinary markers of tubular injury and longitudinal outcomes in stable ambulatory patients. In patients with CKD, urinary neutrophil gelatinase-associated lipocalin (NGAL) has been associated with more rapid progression of kidney disease in an observational study of 96 individuals. 22 Similarly, NGAL was associated with development of incident CKD in the Atherosclerosis Risk in Communities study. 23 In MESA, both urinary IL-18 and KIM-1 were associated with development of incident CKD and/or rapid progression of kidney disease using a case control design, 16 whereas among HIV-infected women in WIHS, elevated levels of urinary IL-18 and KIM-1 were each associated with kidney function decline. 18 In one of the only outpatient studies to evaluate mortality, urinary IL-18 and KIM-1 were also associated with mortality in WIHS. 17 We hypothesized that urinary markers of tubular injury might be associated with mortality for the following reasons. First, CKD is a well accepted risk factor for mortality as well as CVD, 24 and therefore, subclinical kidney injury may also be a risk factor for these outcomes. Second, prior literature has suggested that markers of tubular injury reflect pathologic damage, 12, 13, 15 which may result in tubular dysfunction. In turn, tubular dysfunction may be associated with adverse outcomes through pathways, including mineral metabolism, erythropoeisis, acid-base regulation, and urinary concentration ability. Thus, the specific tubular pathway may lead to mortality risk. Third, the markers of tubular injury may reflect the overall severity of kidney disease or the global burden of CKD risk factors, such as hypertension or diabetes, and thus, they may be a risk factor for all-cause mortality or CVD. Fourth, these biomarkers may reflect global deterioration or injury processes throughout the body. Increased kidney injury or fibrosis may parallel similar processes in lungs, heart, and other organs.
Our results show that urinary KIM-1 is independently related to mortality, suggesting that tubular injury biomarkers may associate with clinically important long-term outcomes in ambulatory persons. We noted some attenuation in the relationship after adjustment for baseline ACR and eGFR cys as well as time-dependent eGFR cys . This attenuation suggests that a component, but not all, of the relationship between KIM-1 and mortality may be through its association with baseline kidney disease and progression of kidney disease. We noted no attenuation in the relationship of KIM-1/cr with mortality after adjusting for several markers of tubulointerstitial function and/or severity of kidney disease risk factors. We acknowledge, however, the possibility of residual confounding, particularly given that tubulointerstitial function and severity or risk factors are difficult to ascertain. The association of KIM-1 with mortality was, however, modest. The lack of a stronger independent association between urinary KIM-1 and mortality and the absence of significant associations between urinary KIM-1 and incident CVD and between urinary IL-18 with either mortality or incident CVD may be because of one of several reasons. First, urinary IL-18 and KIM-1 concentrations may not be accurate proxies for either severity of kidney disease or tubular dysfunction, partly because they are inducible biomarkers released in response to stress. Indeed, it is possible that other urine injury markers, such as NGAL, 25 may be better proxies for tubulointerstitial disease. NGAL has not, however, been assayed in the Health ABC study. Second, these markers may also not be stable enough or have adequate precision in ambulatory elders to capture a process that accelerates mortality risk. Third, the general population may not be the ideal population to evaluate these relationships, because most individuals do not have substantial kidney damage. However, we noted no difference in the associations by level of eGFR or UACR.
In contrast to our results with the tubular injury markers, we noted a strong relationship between higher UACR and both mortality and CVD. These findings are consistent with prior studies, 26 including those studies in the elderly, 27 which have suggested that ACR is a risk factor for these outcomes. Although the exact mechanism relating albuminuria to these outcomes is unknown, it has been hypothesized that albuminuria may be a manifestation of generalized endothelial dysfunction, the severity of CVD risk factors, such as hypertension or diabetes, or the severity of underlying kidney disease. 24 In addition, albuminuria is a well recognized risk factor for progression of kidney disease through several mechanisms, including inhibition of regeneration of podocytes in the glomerular tuft. 28 Progressive kidney disease, in turn, may be associated with CVD and mortality. Albuminuria is also associated with progressive proximal tubular dysfunction and injury, [29] [30] [31] and, therefore, it may be a better marker of total kidney damage compared with markers that only incorporate tubular injury. Our study has several strengths and limitations. The strengths include a large study in an older population with detailed ascertainment of risk factors, covariates, and outcomes and the ability to adjust for well accepted measures of kidney function, including eGFR and ACR. Our measurements of urinary tubular injury have external validity, because they were associated with expected participant characteristics, such as measures of kidney function (UACR and eGFR) and presence of diabetes. We used a laboratory that has extensive experience with these measures. The limitations include the observational nature of the study, which results in our inability to ascribe cause-effect relationships and the possibility of residual confounding. In addition, we do not have detailed measures of either tubular function or kidney pathology. Finally, our urine biomarkers may have degraded during longterm storage, which could lead to measurement error that would bias to weaker results.
In conclusion, urinary KIM-1 had a modest independent association with all-cause mortality, whereas urinary IL-18 was not associated with all-cause mortality or CVD. In contrast, albuminuria was strongly and independently associated with all-cause mortality and CVD. Future studies should evaluate reasons for differences in the prognostic importance of tubular versus glomerular injury markers, whether tubular injury markers are associated with mortality or CVD in the setting of more advanced CKD, and whether tubular injury markers are associated with progression of CKD.
CONCISE METHODS

Design and Participants
The Health ABC cohort comes from a National Institute on Agingsponsored study that enrolled 3075 well functioning men and women ages 70-79 years from two clinical sites in Memphis, Tennessee and Pittsburgh, Pennsylvania. Participant eligibility required self-reported ability to walk 0.25 miles, climb 10 steps, and perform basic activities of daily living without difficulty, the absence of life-threatening illness, and plans to remain in the geographic area for at least 3 years. Participants underwent a half-day evaluation that included medical history, physical activity assessment, physical examination, and radiographic tests. The study was approved by the institutional review boards at the University of Tennessee Health Science Center and the University of Pittsburgh. In addition, the present study was approved by University of California at San Francisco, San Francisco Veterans Affairs Medical Center, and Tufts Medical Center committees on human research.
Exposure Variables
The primary exposure variables were urinary KIM-1, IL-18, and albumin, which were measured concurrently from previously frozen baseline urine samples stored at 280°C. The kidney injury biomarkers were measured at the Cincinnati Children's Hospital Medical Center Biomarker Laboratory. All urine specimens were in continuous storage without prior freeze-thaw. Laboratory personnel were blinded to clinical information about the participants. The urine KIM-1 ELISA was constructed using commercially available reagents (Duoset DY1750; R&D Systems, Inc., Minneapolis, MN). 32 Urine IL-18 was measured using a commercially available ELISA kit (Medical & Biologic Laboratories Co., Nagoya, Japan). 33 The microalbumin assay is based on a particle-enhanced turbidimetric inhibition immunoassay adapted to a clinical chemistry system, which allows direct quantitation of albumin in urine samples (Siemens, Newark, DE). Urine creatinine was measured by a modified Jaffe method on a clinical chemistry analyzer (Siemens). 34 To account for urine volume, the biomarker levels were standardized to urine creatinine. 1 Intra-and interassay coefficients of variation for the urine measures were IL-18, 7.2%/7.5%; KIM-1, 5.6%/4.9%; albumin, 2.3%/6%; and creatinine, 0.6%/1.1%. Minimum detectable values for each biomarker were KIM-1, 59 ng/ml; IL-18, 12.5 pg/ml; albumin, 1.3 mg/dl; and urine creatinine, 0.05 mg/dl. Values that were below detectable were set to the lowest detectable value. ; heart failure and CHD (defined as myocardial infarction, angina, or coronary artery bypass); physical exam findings (including SBP); and blood tests (including serum albumin and CRP). Cystatin C was measured by a particle-enhanced immunonephelometric assay (N Latex Cystatin C) using a BNII Nephelometer (Dade Behring, Inc., Deerfield, IL). GFR was estimated using the 2012 Chronic Kidney Disease Epidemiology equation for cystatin C, which includes age and sex. 36 
Outcome Variables Mortality
Statistical Analyses
Participants were divided into quartiles of KIM-1/cr (quartiles of IL-18 and UACR are provided in Supplemental Tables 1 and 2) , and the distributions of covariates across groups were evaluated. Baseline characteristics of participants were compared using t or chi-squared tests as appropriate. Spearman correlations between KIM-1/cr, IL-18/ cr, eGFR cys , and UACR were calculated. We evaluated the association of KIM-1/cr, IL-18/cr, and UACR with the presence of CKD defined by eGFR cys ,60 ml/min per 1.73 m 2 using multivariable logistic regression analyses adjusted for demographics and CVD risk factors. CVD event and death rates were calculated per 100 person-years and reported as percent per person-year. Cox proportional hazards models were used to investigate the associations of KIM-1/cr, IL-18/cr, and UACR with both all-cause mortality and CVD events, while censoring for non-CVD mortality. Models were nested and adjusted in stages for (1) age, sex, race, site, and education status; (2) traditional CVD risk factors (diabetes, hypertension, SBP, smoking, prevalent CHD, prevalent heart failure, serum albumin, and CRP); and (3) eGFR cys and UACR in the tubular injury models and eGFR cys in albuminuria models. Given the skewed distribution of the predictors, models were initially evaluated with the exposure variable transformed to the log base 2, presented per doubling, and subsequently, presented in quartiles. UACR was also evaluated using the clinical cutpoint of 30 mg/g. The proportional hazards assumption was satisfied for all models, with P values for Schoenfeld residuals.0.20. We evaluated interactions of the tubular injury markers with eGFR. or #60 ml/min per 1.73 m 2 , ACR.30 mg/g or #30 mg/g, sex, and race for the outcomes of mortality and CVD. We conducted analyses using S-Plus (version 8.0; Tibco, Seattle, WA) and SPSS statistical software (version 16.0.2; SPSS, Inc., Chicago, IL).
Sensitivity Analyses
We performed several sensitivity analyses to explore potential mechanisms relating kidney injury markers to outcomes. First, given that the association of urine injury markers with outcomes may be through their effects on progression of kidney disease, we evaluated the association of the injury markers with progression of kidney disease using logistic regression and linear mixed models and whether the relationships were attenuated after adjustment for time-dependent changes in eGFR cys . Cystatin C was measured at baseline, year 3, and year 10 in the Health ABC study, and the cystatin C values were calibrated to each other. Change in kidney function was defined as eGFR cys change in milliliters per minute per 1.73 m 2 per year, and rapid kidney function decline was defined as eGFR cys loss of .3 ml/min per 1.73 m 2 per year; prior studies have shown that this rate is associated with increased CVD morbidity and mortality, independent of baseline eGFR. 37, 38 Second, given that urinary injury markers may reflect tubulointerstitial dysfunction, which in turn, is associated with CVD or mortality, we evaluated whether adjustment for baseline serum bicarbonate, parathyroid hormone, serum phosphorus, and serum hemoglobin attenuated the results. Third, because urine injury markers may reflect the severity of diabetes or hypertension, we evaluated whether adjustment for baseline hemoglobin A1C or time-dependent SBP, respectively, attenuated the results.
